Brought to you by 
Janssen Biotech licenses ImmuNext's VISTA therapeutics; ImmuNext regains rights to CI8993
09 Nov 2021
Executive Summary
Johnson & Johnson’s Janssen Biotech Inc. has licensed exclusive global development and commercialization rights to ImmuNext Inc.’s (oncology and immunology therapeutics) preclinical cancer immunotherapies, which antagonize the VISTA (V-region immunoglobulin-containing suppressor of T-cell activation) signaling pathway.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Janssen Biotech licenses ImmuNext's VISTA therapeutics; ImmuNext regains rights to CI8993
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice